November 13, 2023 / eMedClub News /--Recently, CAR-T biotechnology company CARGO Therapeutics, Inc. submitted an IPO application to the SEC, planning to list on NASDAQ.CARGO Therapeutics Hopes in Life SciencesIn a bleak year for IPOs, it became one of the largest listed companies on Nasdaq.CARGO Therapeutics, Inc. disclosed its stock issuance plan on Monday morning this week, planning to issue 18.75 million shares at a price of $15 to $17 per share. According to the latest filing with the U.S. Securities and Exchange Commission, this would generate approximately $300 million in net proceeds (about 2.185 billion yuan) at the midpoint. If the underwriters purchase an additional 2.8 million shares, the net proceeds will increase to approximately $316 million.If investors buy into this CAR-T company's stock and its share price eventually stabilizes at $16, the scale of its stock issuance will be almost equivalent to the $300 million raised by Apogee Therapeutics in July, but lower than the $311 million raised by RayzeBio in September and the $540 million raised by Acelyrin in May. Notably, these two companies already have products that are either successfully commercialized or nearing commercialization.According to reports,CARGO Therapeutics, founded in 2021, is dedicated to advancing "next-generation" cell therapies and was established by cell therapy experts from Stanford University.Crystal Mackall, one of the company's founders, is the founding director of the Stanford Cancer Cell Therapy Center and the director of the Stanford Parker Cancer Immunotherapy Research Institute. She has served on the Scientific Advisory Boards of multiple biotechnology and pharmaceutical companies.The other founders are also mostlyScholars from the Stanford University School of Medicine.
The CEO of the company, Gina Chapman, has over 30 years of commercial and operational experience in the biopharmaceutical industry. She previously served as the Senior Vice President and Head of the Business Unit at Genentech, a member of the Roche Group, where she was responsible for overseeing the development and execution of business unit and therapeutic area strategies during her 15-year tenure.
Committed to Overcoming the Pain Points of CAR-T
The core feature of this company lies in the differentiation of indications and products. The indication for the company's first product is relapse after CAR-T treatment, and it has made achievements in addressing antigen escape, loss of co-stimulatory signals, and insufficient persistence.
CARGOThe future strategy of Cargo Therapeutics is to develop novel CAR-T therapies to overcome the existing pain points in current cell treatments. Although commercially available autologous CAR-T therapies have made significant progress, these therapies can only cure less than half of cancer patients. In addition, due to other challenges such as manufacturing, supply limitations, slow turnaround times, and reimbursement issues, too many patients are unable to access these potentially curative therapies. The team at Cargo Therapeutics is highly focused on seeking innovative solutions to achieve better outcomes in cancer treatment.The company is building a scientific platform technology that can integrate various complex functions and customized engineering components, supporting multi-specificity and multi-functional CAR-T programs. The company is engineering CAR-T cells using enhanced genetic material to overcome various tumor resistance mechanisms, counteract immune suppression in hematologic malignancies and solid tumors, and evade immune rejection in allogeneic settings.
In March this year,CARGO Therapeutics Announces Completion of $200 Million Series A Financing, with Participation from Multiple Renowned InvestorsVenture Capital Institution, will be used to advance the development of its autologous CD22 CAR-T cell therapy candidate CRG-022, which is currently in Phase I clinical trials.
As is known to all, the pharmaceutical market is currently in a downturn, and the threshold for IPOs of pharmaceutical companies has also increased significantly. According to Kevin Eisele, Managing Director and Co-Head of Chicago Healthcare Equity Capital Markets, in 2020 and 2021, entrepreneurs only needed a zip code and an idea to secure funding, but now, some entrepreneurs struggle to obtain funds even with good ideas. Another industry expert commented, "When the IPO market reopens, it will start with these A+ premium companies. Banks want to lead investors to participate in the most sought-after deals. As the market gradually begins to accept new stock offerings, you'll see more and more companies that may not be suitable for the current market."
Indeed, this year about 15 biotech companies went public on Nasdaq, but investors were not buying. Most of them saw their stock prices fall below the issue price, and Cargo Therapeutics will become one of the few cell and gene therapy manufacturers. Last Friday, Lexeo Therapeutics, a gene therapy startup, went public with a smaller IPO than originally planned, and its stock price fell nearly 9% on the first day of trading.CARGO Therapeutics, Inc. is set to become the sixth biotech company to go public this fall. With its advanced technology, sufficiently differentiated products, and the backing of well-known industry figures, it is expected to gain investor support. Let's wait and see.1.https://mp.weixin.qq.com/s/pJets7UpcN92fRYlRyno8Q2.https://endpts.com/cargo-therapeutics-eyes-one-of-2023s-largest-ipos-in-a-dull-year-for-listings/Statement and Copyright Notice
Disclaimer: This article aims to convey industry development information and explore the frontier progress of biomedicine. The content of the article represents the author's viewpoint and does not represent the position of EurekaMed, nor does it constitute any value judgment, investment advice, or medical guidance. If necessary, please consult a professional for investment or visit a正规 hospital for medical advice.
Copyright Statement:This article is from the content team of Yima Guest. Individuals are welcome to share it on their social media platforms, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For reprint authorization, please leave a message at the bottom of the article.
Dian Dian "Share”、“Like" and "In View"，Give me a little recharge~"
